Double Bond Pharmaceutical International AB - Class B

XSAT:DBP B (Sweden)   B
kr 0.72 (+1.41%) May 14
At Loss
P/B:
12.85
Market Cap:
kr 68.66M ($ 6.36M)
Enterprise V:
kr 64.72M ($ 6.00M)
Volume:
249.36K
Avg Vol (2M):
285.00K
Warning! GuruFocus detected 3 Severe warning signs with DBP B. Try a 7-Day Free Trial to check it out.
Volume:
249.36K
Market Cap kr:
68.66M
Market Cap $:
6.36M
At Loss
Avg Vol (2M):
285.00K
Enterprise Value kr:
64.72M
Enterprise Value $:
6.00M
PB Ratio:
12.85
Alerts Website Sources Stock PDF
Dataset
Financial Download Manual of Stocksâ„¢

Business Description

Double Bond Pharmaceutical International AB

ISIN : SE0007185525
http://www.doublebp.com
Virdings Alle 32B, Uppsala, SWE, 75450

Share Class Description:

XSAT:DBP B: B
Compare
Compare
XSAT:APTAOSTO:ONCOZOSTO:CMOTEC BOSTO:MODTXOSTO:FLUIOSTO:2CUREXXSAT:CHOSAOSTO:PILAOSTO:LPGOOSTO:SCOLOCSE:NOVO BVRTXREGNASX:CSLSGENXKRX:207940MRNAHKSE:02269XBRU:ARGXBNTX
Traded in other countries / regions
DBP B.Sweden
IPO Date
2015-07-10
Description
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.

Financial Strength

6/10
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.46
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.25
Distress
Grey
Safe
Beneish M-Score -14.86
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

9/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -14
3-Year EBITDA Growth Rate 18.9
3-Year EPS without NRI Growth Rate 25.1
3-Year Book Growth Rate -44.6
Future 3-5Y Total Revenue Growth Rate 27.9

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 76.2
9-Day RSI 65.22
14-Day RSI 58.3
6-1 Month Momentum % 97.25
12-1 Month Momentum % 49.58

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.8
Quick Ratio 0.8
Cash Ratio 0.63
Days Inventory 179.61
Days Sales Outstanding 16.83
Days Payable 38.69

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -22.1

Profitability Rank

2/10
Name Current Vs Industry Vs History
Gross Margin % -241.07
Operating Margin % -980.02
Net Margin % -1264.7
FCF Margin % 913.79
ROE % -158.78
ROA % -116.79
ROIC % -112.58
ROC (Joel Greenblatt) % -8124.06
ROCE % -157.54

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 48.01
PB Ratio 12.85
Price-to-Tangible-Book 14.4
Price-to-Free-Cash-Flow 5.5
Price-to-Operating-Cash-Flow 5.5
EV-to-EBIT -3.76
EV-to-Forward-EBIT -3.3
EV-to-EBITDA -3.81
EV-to-Revenue 47.21
EV-to-Forward-Revenue 23.01
EV-to-FCF 4.47
Earnings Yield (Greenblatt) % -26.6
FCF Yield % 18.24

Financials (Next Earnings Date:2024-08-27)

XSAT:DBP B's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Double Bond Pharmaceutical International AB Executives

Details

GF Value: kr0.53

XSAT:DBP B

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 1.371
EPS (TTM) (kr) -0.184
Beta 0
Volatility % 128.23
14-Day RSI 58.3
14-Day ATR (kr) 0.08651
20-Day SMA (kr) 0.6269
12-1 Month Momentum % 49.58
52-Week Range (kr) 0.251 - 1.995
Shares Outstanding (Mil) 94.35

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Double Bond Pharmaceutical International AB Filings

Filing Date Document Date Form
No Filing Data

Double Bond Pharmaceutical International AB Stock Events

Financials Calendars
Event Date Price(kr)
No Event Data

Double Bond Pharmaceutical International AB Frequently Asked Questions

What is Double Bond Pharmaceutical International AB(XSAT:DBP B)'s stock price today?
The current price of XSAT:DBP B is kr0.72. The 52 week high of XSAT:DBP B is kr2.00 and 52 week low is kr0.25.
When is next earnings date of Double Bond Pharmaceutical International AB(XSAT:DBP B)?
The next earnings date of Double Bond Pharmaceutical International AB(XSAT:DBP B) is 2024-08-27.
Does Double Bond Pharmaceutical International AB(XSAT:DBP B) pay dividends? If so, how much?
Double Bond Pharmaceutical International AB(XSAT:DBP B) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.